FDA: anti-counterfeiting successes are 'drop in the bucket'; Pfizer sells PR plant to Mexico's Neolpharma;

> The FDA says its anti-counterfeiting successes are just "a drop in the bucket." Report

> Mylan ($MYL) is buying an oncology drug production plant in India for $32.5 million. Article

> Pfizer ($PFE) has sold one of the Puerto Rico plants it earmarked for closure to Mexican drugmaker Neolpharma. Article

> Biostar Pharmaceuticals has inked a $3 million deal to manufacture drugs for a Chinese hospital. Article

> The cost of many medicines in Ireland are to drop 10% after the government struck a deal with manufacturers. Article

> Tris Pharma has leased a New Jersey warehouse to accommodate a spike in manufacturing activity. Article

Suggested Articles

Pfizer is ponying up $500 million on top of $100 million already committed to a gene therapy manufacturing facility in North Carolina.

Hikma says it has picked up some pipeline products and nasal and sublingual spray equipment from Insys Therapeutics' bankruptcy.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.